How to Differentiate Benign from Malignant Adrenocortical Tumors?

Simple Summary Adrenocortical carcinoma is a rare cancer with a poor prognosis. Adrenal tumors are, however, commonly identified in clinical practice. Discrimination between benign and malignant adrenal tumors is of great importance to determine the appropriate treatment and follow-up strategy. This review summarizes the current diagnostic strategies and challenges to distinguish benign from malignant adrenal lesions. We will focus both on radiological and biochemical assessments, enabling diagnosis of the adrenal lesion preoperatively, and on histopathological and a wide variety of molecular assessments that can be done after surgical removal of the adrenal lesion. Furthermore, new non-invasive strategies such as liquid biopsies, in which blood samples are used to study circulating tumor cells, tumor DNA and microRNA, will be addressed in this review. Abstract Adrenocortical carcinoma (ACC) is a rare cancer with a poor prognosis. Adrenal incidentalomas are, however, commonly identified in clinical practice. Discrimination between benign and malignant adrenal tumors is of great importance considering the large differences in clinical behavior requiring different strategies. Diagnosis of ACC starts with a thorough physical examination, biochemical evaluation, and imaging. Computed tomography is the first-level imaging modality in adrenal tumors, with tumor size and Hounsfield units being important features for determining malignancy. New developments include the use of urine metabolomics, also enabling discrimination of ACC from adenomas preoperatively. Postoperatively, the Weiss score is used for diagnosis of ACC, consisting of nine histopathological criteria. Due to known limitations as interobserver variability and lack of accuracy in borderline cases, much effort has been put into new tools to diagnose ACC. Novel developments vary from immunohistochemical markers and pathological scores, to markers at the level of DNA, methylome, chromosome, or microRNA. Molecular studies have provided insights into the most promising and most frequent alterations in ACC. The use of liquid biopsies for diagnosis of ACC is studied, although in a small number of patients, requiring further investigation. In this review, current diagnostic modalities and challenges in ACC will be addressed.

[1]  A. Lam Adrenocortical Carcinoma: Updates of Clinical and Pathological Features after Renewed World Health Organisation Classification and Pathology Staging , 2021, Biomedicines.

[2]  E. Caoili,et al.  18F-FDG-PET/CT Evaluation of Indeterminate Adrenal Masses in Non-Cancer Patients. , 2021, The Journal of clinical endocrinology and metabolism.

[3]  M. Mannelli,et al.  Prognostic and Monitoring Value of Circulating Tumor Cells in Adrenocortical Carcinoma: A Preliminary Monocentric Study , 2020, Cancers.

[4]  Bangshun He,et al.  The diagnostic and prognostic values of microRNA-196a in cancer , 2020, Bioscience reports.

[5]  R. Aneja,et al.  Adrenal gland fine needle aspiration: a multi-institutional analysis of 139 cases. , 2020, Journal of the American Society of Cytopathology.

[6]  Han-Zhong Li,et al.  Sum of High-Risk Gene Mutation (SHGM): A Novel Attempt to Assist Differential Diagnosis for Adrenocortical Carcinoma with Benign Adenoma, Based on Detection of Mutations of Nine Target Genes , 2020, Biochemical Genetics.

[7]  G. Hutvagner,et al.  Key MicroRNA’s and Their Targetome in Adrenocortical Cancer , 2020, Cancers.

[8]  Michael Biehl,et al.  Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study , 2020, The lancet. Diabetes & endocrinology.

[9]  B. Eisenberg,et al.  Molecular genomic profiling of adrenocortical cancers in clinical practice. , 2020, Surgery.

[10]  M. Papotti,et al.  The IGF2 methylation score for adrenocortical cancer: an ENSAT validation study. , 2020, Endocrine-related cancer.

[11]  E. Kebebew,et al.  Adrenocortical tumors have a distinct, long, non-coding RNA expression profile and LINC00271 is downregulated in malignancy. , 2020, Surgery.

[12]  S. Pakbaz,et al.  A Diagnostic Approach to Adrenocortical Tumors. , 2019, Surgical pathology clinics.

[13]  P. Igaz,et al.  Comparison of plasma and urinary microRNA-483-5p for the diagnosis of adrenocortical malignancy. , 2019, Journal of biotechnology.

[14]  P. Igaz Circulating microRNAs in adrenal tumors , 2019, Current opinion in endocrinology, diabetes, and obesity.

[15]  T. Koehler,et al.  Adrenocortical oncocytic neoplasm: A systematic review☆ , 2018, Surgery.

[16]  Eric Baudin,et al.  European Society of Endocrinology Clinical Practice Guidelines on the Management of Adrenocortical Carcinoma in Adults, in collaboration with the European Network for the Study of Adrenal Tumors. , 2018, European journal of endocrinology.

[17]  Chin-Lee Wu,et al.  Co-expression Network Analysis of Biomarkers for Adrenocortical Carcinoma , 2018, Front. Genet..

[18]  J. Bertherat,et al.  MiR‐483‐5p and miR‐139‐5p promote aggressiveness by targeting N‐myc downstream‐regulated gene family members in adrenocortical cancer , 2018, International journal of cancer.

[19]  B. Amgai,et al.  The Characteristics and Trends in Adrenocortical Carcinoma: A United States Population Based Study , 2018, Journal of clinical medicine research.

[20]  E. Baudin,et al.  Clinicopathological description of 43 oncocytic adrenocortical tumors: importance of Ki-67 in histoprognostic evaluation , 2018, Modern Pathology.

[21]  A. Tabarin,et al.  Diagnostic accuracy of computed tomography to identify adenomas among adrenal incidentalomas in an endocrinological population. , 2018, European journal of endocrinology.

[22]  M. Mannelli,et al.  Adrenocortical carcinoma: the dawn of a new era of genomic and molecular biology analysis , 2018, Journal of Endocrinological Investigation.

[23]  S. Asa,et al.  Diagnostic and Prognostic Biomarkers of Adrenal Cortical Carcinoma , 2018, The American journal of surgical pathology.

[24]  J. Bertherat,et al.  Genetics of tumors of the adrenal cortex. , 2017, Endocrine-related cancer.

[25]  M. Sibony,et al.  Detection and monitoring of circulating tumor DNA in adrenocortical carcinoma. , 2017, Endocrine-related cancer.

[26]  W. Dinjens,et al.  Identification of Mutations in Cell-Free Circulating Tumor DNA in Adrenocortical Carcinoma: A Case Series. , 2017, The Journal of clinical endocrinology and metabolism.

[27]  S. Challa,et al.  Diagnosis of Adrenocortical Tumors by Reticulin Algorithm , 2017, Indian journal of endocrinology and metabolism.

[28]  P. Igaz,et al.  Evaluation and diagnostic potential of circulating extracellular vesicle-associated microRNAs in adrenocortical tumors , 2017, Scientific Reports.

[29]  S. Gelmini,et al.  New insights in the clinical and translational relevance of miR483-5p in adrenocortical cancer , 2017, Oncotarget.

[30]  Michael R. Speicher,et al.  Emerging concepts in liquid biopsies , 2017, BMC Medicine.

[31]  K. Jażdżewski,et al.  Next-generation sequencing reveals microRNA markers of adrenocortical tumors malignancy , 2017, Oncotarget.

[32]  M. Papotti,et al.  Validation of the prognostic role of the "Helsinki Score" in 225 cases of adrenocortical carcinoma. , 2017, Human pathology.

[33]  S. Kopetz,et al.  Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  M. Papotti,et al.  Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysis. , 2016, Human pathology.

[35]  W. Young,et al.  Procedural and clinical outcomes of percutaneous adrenal biopsy in a high‐risk population for adrenal malignancy , 2016, Clinical endocrinology.

[36]  B. Leggett,et al.  RNF43 and ZNRF3 are commonly altered in serrated pathway colorectal tumorigenesis , 2016, Oncotarget.

[37]  P. V. van Koetsveld,et al.  Methylation of IGF2 regulatory regions to diagnose adrenocortical carcinomas. , 2016, Endocrine-related cancer.

[38]  J. Deeks,et al.  MANAGEMENT OF ENDOCRINE DISEASE: Imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis , 2016, European journal of endocrinology.

[39]  Fares Alahdab,et al.  DIAGNOSIS OF ENDOCRINE DISEASE: The diagnostic performance of adrenal biopsy: a systematic review and meta-analysis. , 2016, European journal of endocrinology.

[40]  A. Tabarin,et al.  Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. , 2016, European journal of endocrinology.

[41]  Qi Zheng,et al.  ZNRF3 is downregulated in papillary thyroid carcinoma and suppresses the proliferation and invasion of papillary thyroid cancer cells , 2016, Tumor Biology.

[42]  E. Bessonova,et al.  Different Types of Urinary Steroid Profiling Obtained by High-Performance Liquid Chromatography and Gas Chromatography-Mass Spectrometry in Patients with Adrenocortical Carcinoma , 2016, Hormones and Cancer.

[43]  Benjamin J Raphael,et al.  Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. , 2016, Cancer cell.

[44]  Klaus Pantel,et al.  Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. , 2016, Cancer discovery.

[45]  Andrew P Stubbs,et al.  An International Ki67 Reproducibility Study in Adrenal Cortical Carcinoma , 2016, The American journal of surgical pathology.

[46]  W. Young,et al.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline. , 2016, The Journal of clinical endocrinology and metabolism.

[47]  Melissa J. Fullwood,et al.  Roles, Functions, and Mechanisms of Long Non-coding RNAs in Cancer , 2016, Genom. Proteom. Bioinform..

[48]  E. Caoili,et al.  5th International ACC Symposium: Imaging for Diagnosis and Surveillance of Adrenal Tumors—New Advances and Reviews of Old Concepts , 2016, Hormones and Cancer.

[49]  G. Scagliotti,et al.  Pitfalls in the diagnosis of adrenocortical tumors: a lesson from 300 consultation cases. , 2015, Human pathology.

[50]  R. Verhaak,et al.  Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma. , 2015, Cancer research.

[51]  E. Caoili,et al.  Radiographic Characteristics of Adrenal Masses Preceding the Diagnosis of Adrenocortical Cancer , 2015, Hormones and Cancer.

[52]  I. Kema,et al.  Diagnostic Value of Urinary Steroid Profiling in the Evaluation of Adrenal Tumors , 2015, Hormones and Cancer.

[53]  S. Chowdhury,et al.  Histopathological study of adrenocortical masses with special references to Weiss score, Ki-67 index and p53 status. , 2015, Indian journal of pathology & microbiology.

[54]  R. Kanthan,et al.  Diagnostic and prognostic features in adrenocortical carcinoma: a single institution case series and review of the literature , 2015, World Journal of Surgical Oncology.

[55]  C. Haglund,et al.  Helsinki score-a novel model for prediction of metastases in adrenocortical carcinomas. , 2015, Human pathology.

[56]  Annabelle L. Fonseca,et al.  Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. , 2015, The Journal of clinical endocrinology and metabolism.

[57]  Claudia Eichler-Jonsson,et al.  Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children's oncology group study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  P. Igaz,et al.  MicroRNAs in adrenal tumors: relevance for pathogenesis, diagnosis, and therapy , 2015, Cellular and Molecular Life Sciences.

[59]  M. Papotti,et al.  Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. , 2015, The Journal of clinical endocrinology and metabolism.

[60]  Andrew P Stubbs,et al.  Automated Selection of Hotspots (ASH): enhanced automated segmentation and adaptive step finding for Ki67 hotspot detection in adrenal cortical cancer , 2014, Diagnostic Pathology.

[61]  M. Al-Haddad,et al.  Role of endoscopic ultrasound fine-needle aspiration evaluating adrenal gland enlargement or mass. , 2014, World journal of nephrology.

[62]  P. Stephens,et al.  Next-generation sequencing of adrenocortical carcinoma reveals new routes to targeted therapies , 2014, Journal of Clinical Pathology.

[63]  H. Macapinlac,et al.  Impact of 18F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[64]  Eric Baudin,et al.  Integrated genomic characterization of adrenocortical carcinoma , 2014, Nature Genetics.

[65]  P. Igaz,et al.  Analysis of circulating microRNAs in adrenocortical tumors , 2014, Laboratory Investigation.

[66]  J. Bertherat,et al.  Mass-array screening of frequent mutations in cancers reveals RB1 alterations in aggressive adrenocortical carcinomas. , 2014, European journal of endocrinology.

[67]  T. Giordano,et al.  CT imaging characteristics of oncocytic adrenal neoplasms (OANs): comparison with adrenocortical carcinomas , 2014, Abdominal Imaging.

[68]  M. Papotti,et al.  Comparative diagnostic and prognostic performances of the hematoxylin-eosin and phospho-histone H3 mitotic count and Ki-67 index in adrenocortical carcinoma , 2014, Modern Pathology.

[69]  T. Fojo,et al.  MiR-34a and miR-483-5p are candidate serum biomarkers for adrenocortical tumors. , 2013, Surgery.

[70]  Dachun Zhao,et al.  Distinguishing adrenal cortical carcinomas and adenomas: a study of clinicopathological features and biomarkers , 2013, Histopathology.

[71]  M. Fassnacht,et al.  Update in adrenocortical carcinoma. , 2013, The Journal of clinical endocrinology and metabolism.

[72]  A. Rosenwald,et al.  Single Nucleotide Polymorphism Array Profiling of Adrenocortical Tumors - Evidence for an Adenoma Carcinoma Sequence? , 2013, PloS one.

[73]  M. Papotti,et al.  The Reticulin Algorithm for Adrenocortical Tumor Diagnosis: A Multicentric Validation Study on 245 Unpublished Cases , 2013, The American journal of surgical pathology.

[74]  J. Bertherat,et al.  Serum miR-483-5p and miR-195 are predictive of recurrence risk in adrenocortical cancer patients. , 2013, Endocrine-related cancer.

[75]  M. Paglierani,et al.  Detection of circulating tumor cells in patients with adrenocortical carcinoma: a monocentric preliminary study. , 2013, The Journal of clinical endocrinology and metabolism.

[76]  J. Dieleman,et al.  Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. , 2013, European journal of cancer.

[77]  M. Malumbres,et al.  miRNAs and cancer: an epigenetics view. , 2013, Molecular aspects of medicine.

[78]  A. Buck,et al.  [¹²³I]Iodometomidate imaging in adrenocortical carcinoma. , 2013, The Journal of clinical endocrinology and metabolism.

[79]  E. Baudin,et al.  Molecular screening for a personalized treatment approach in advanced adrenocortical cancer. , 2013, The Journal of clinical endocrinology and metabolism.

[80]  J. Dieleman,et al.  Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993 , 2013 .

[81]  A. Buck,et al.  [123I]Iodometomidate imaging in adrenocortical carcinoma , 2013 .

[82]  A. Buck,et al.  Functional characterization of adrenal lesions using [123I]IMTO-SPECT/CT. , 2013, The Journal of clinical endocrinology and metabolism.

[83]  I. Yasuda,et al.  Preoperative routine evaluation of bilateral adrenal glands by endoscopic ultrasound and fine-needle aspiration in patients with potentially resectable lung cancer , 2013, Endoscopy.

[84]  Annabelle L. Fonseca,et al.  Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors , 2012, Genes, chromosomes & cancer.

[85]  V. Viallon,et al.  Adrenocortical Tumors: Improving the Practice of the Weiss System Through Virtual Microscopy A National Program of the French Network INCa-COMETE , 2012, The American journal of surgical pathology.

[86]  P. Meltzer,et al.  DNA methylation profiling identifies global methylation differences and markers of adrenocortical tumors. , 2012, The Journal of clinical endocrinology and metabolism.

[87]  E. Lalli,et al.  Dysregulation of microRNAs in adrenocortical tumors , 2012, Molecular and Cellular Endocrinology.

[88]  J. Bertherat,et al.  Clinical and pathophysiological implications of chromosomal alterations in adrenocortical tumors: an integrated genomic approach. , 2012, The Journal of clinical endocrinology and metabolism.

[89]  M. Papotti,et al.  Oncocytic Adrenocortical Tumors: Diagnostic Algorithm and Mitochondrial DNA Profile in 27 Cases , 2011, The American journal of surgical pathology.

[90]  S. Hahner,et al.  Metomidate-Based Imaging of Adrenal Masses , 2011, Hormones & cancer.

[91]  Michael Biehl,et al.  Urine Steroid Metabolomics as a Biomarker Tool for Detecting Malignancy in Adrenal Tumors , 2011, The Journal of clinical endocrinology and metabolism.

[92]  C. Larsson,et al.  The role of microRNA deregulation in the pathogenesis of adrenocortical carcinoma , 2011, Endocrine-related cancer.

[93]  T. Fojo,et al.  MicroRNA profiling of adrenocortical tumors reveals miR‐483 as a marker of malignancy , 2011, Cancer.

[94]  K. Schmid,et al.  Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours , 2011, Journal of Clinical Pathology.

[95]  M. Platten,et al.  Oncocytic adrenocortical neoplasms--a clinicopathologic study of 13 new cases emphasizing the importance of their recognition. , 2011, Human pathology.

[96]  J. Bertherat,et al.  Transcriptome analysis of adrenocortical cancers: from molecular classification to the identification of new treatments. , 2011, Endocrine-related cancer.

[97]  M. Kalra,et al.  Characterization of adrenal masses by using FDG PET: a systematic review and meta-analysis of diagnostic test performance. , 2011, Radiology.

[98]  Martin Fassnacht,et al.  Adrenocortical carcinoma: a clinician's update , 2011, Nature Reviews Endocrinology.

[99]  F. Tissier Classification of adrenal cortical tumors: what limits for the pathological approach? , 2010, Best practice & research. Clinical endocrinology & metabolism.

[100]  F. Beuschlein,et al.  Deficits in the management of patients with adrenocortical carcinoma in Germany. , 2010, Deutsches Arzteblatt international.

[101]  L. Nieman,et al.  Approach to the patient with an adrenal incidentaloma. , 2010, The Journal of clinical endocrinology and metabolism.

[102]  F. Beuschlein,et al.  High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. , 2010, The Journal of clinical endocrinology and metabolism.

[103]  M. Papotti,et al.  Adrenocortical Tumors With Myxoid Features: A Distinct Morphologic and Phenotypical Variant Exhibiting Malignant Behavior , 2010, The American journal of surgical pathology.

[104]  P. Igaz,et al.  Meta-analysis of adrenocortical tumour genomics data: novel pathogenic pathways revealed , 2010, Oncogene.

[105]  C. Leux,et al.  18F-FDG PET/CT in the characterization and surgical decision concerning adrenal masses: a prospective multicentre evaluation , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[106]  J. Bertherat,et al.  The pathophysiology, diagnosis and prognosis of adrenocortical tumors revisited by transcriptome analyses , 2010, Trends in Endocrinology & Metabolism.

[107]  F. Montorsi,et al.  The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation. , 2010, European journal of cancer.

[108]  Jeffrey E. Lee,et al.  Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma , 2009, Cancer.

[109]  Anthony J Gill,et al.  miR-195 and miR-483-5p Identified as Predictors of Poor Prognosis in Adrenocortical Cancer , 2009, Clinical Cancer Research.

[110]  M. Papotti,et al.  Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification , 2009, Histopathology.

[111]  P. Igaz,et al.  Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. , 2009, Endocrine-related cancer.

[112]  C. Larsson,et al.  Transcriptional profiling enables molecular classification of adrenocortical tumours. , 2009, European journal of endocrinology.

[113]  A. Gill,et al.  Microarray gene expression and immunohistochemistry analyses of adrenocortical tumors identify IGF2 and Ki-67 as useful in differentiating carcinomas from adenomas. , 2009, Endocrine-related cancer.

[114]  L. Weiss,et al.  The Weiss system for evaluating adrenocortical neoplasms: 25 years later. , 2009, Human pathology.

[115]  Martin Fassnacht,et al.  Clinical management of adrenocortical carcinoma. , 2009, Best practice & research. Clinical endocrinology & metabolism.

[116]  Bertrand Dousset,et al.  Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  Paul G. Gauger,et al.  Molecular Classification and Prognostication of Adrenocortical Tumors by Transcriptome Profiling , 2009, Clinical Cancer Research.

[118]  F. Beuschlein,et al.  Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma , 2009, Cancer.

[119]  A. Mcnicol,et al.  A Diagnostic Approach to Adrenal Cortical Lesions , 2008, Endocrine pathology.

[120]  R. Yeh,et al.  Identification of biomarkers of adrenocortical carcinoma using genomewide gene expression profiling. , 2008, Archives of surgery.

[121]  R. Reznek,et al.  The optimal imaging of adrenal tumours: a comparison of different methods. , 2007, Endocrine-related cancer.

[122]  L. Bastian,et al.  Cortisol as a possible marker of metastatic adrenocortical carcinoma: a case report with 3-year follow-up. , 2007, Anticancer research.

[123]  M. Yun,et al.  Analysis of adrenal masses by 18F‐FDG positron emission tomography scanning , 2007, International journal of clinical practice.

[124]  C. Elie,et al.  Somatic TP53 Mutations Are Relatively Rare among Adrenocortical Cancers with the Frequent 17p13 Loss of Heterozygosity , 2007, Clinical Cancer Research.

[125]  V. Rousson,et al.  IGFII and MIB1 immunohistochemistry is helpful for the differentiation of benign from malignant adrenocortical tumours , 2006, Histopathology.

[126]  P. Choyke ACR Appropriateness Criteria on incidentally discovered adrenal mass. , 2006, Journal of the American College of Radiology : JACR.

[127]  M. Bergström,et al.  [11C]metomidate positron emission tomography of adrenocortical tumors in correlation with histopathological findings. , 2006, The Journal of clinical endocrinology and metabolism.

[128]  G. Scagliotti,et al.  Prevalence of adrenal incidentaloma in a contemporary computerized tomography series , 2006, Journal of endocrinological investigation.

[129]  D. Bartsch,et al.  Analysis by cDNA microarrays of gene expression patterns of human adrenocortical tumors. , 2006, European journal of endocrinology.

[130]  Q. Duh,et al.  Risk assessment in 457 adrenal cortical carcinomas: how much does tumor size predict the likelihood of malignancy? , 2006, Journal of the American College of Surgeons.

[131]  Joakim Lundeberg,et al.  Expression profiling of adrenocortical neoplasms suggests a molecular signature of malignancy. , 2005, Surgery.

[132]  J. Bertherat,et al.  Molecular genetics of adrenocortical tumours, from familial to sporadic diseases. , 2005, European journal of endocrinology.

[133]  J. Bertherat,et al.  Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. , 2005, Cancer research.

[134]  F. Berger,et al.  Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic Acid microarrays identifies several candidate genes as markers of malignancy. , 2005, The Journal of clinical endocrinology and metabolism.

[135]  Allan Siperstein,et al.  Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas/hyperplasias from nonadenomas: Cleveland Clinic experience. , 2005, The Journal of clinical endocrinology and metabolism.

[136]  M. Bisceglia,et al.  Adrenocortical Oncocytic Tumors: Report of 10 Cases and Review of the Literature , 2004, International journal of surgical pathology.

[137]  W. Wadsak,et al.  Positron emission tomography imaging of adrenal masses: 18F-fluorodeoxyglucose and the 11β-hydroxylase tracer 11C-metomidate , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[138]  K. Någren,et al.  Imaging of adrenal incidentalomas with PET using (11)C-metomidate and (18)F-FDG. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[139]  C. Cordon-Cardo,et al.  Adrenocortical Adenoma and Carcinoma: Histopathological and Molecular Comparative Analysis , 2003, Modern Pathology.

[140]  L. Thompson,et al.  Adrenal Cortical Neoplasms in the Pediatric Population: A Clinicopathologic and Immunophenotypic Analysis of 83 Patients , 2003, The American journal of surgical pathology.

[141]  Paul G Gauger,et al.  Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. , 2003, The American journal of pathology.

[142]  P. Devos,et al.  Weiss System Revisited: A Clinicopathologic and Immunohistochemical Study of 49 Adrenocortical Tumors , 2002, The American journal of surgical pathology.

[143]  P. Heikkilä,et al.  Association of H19 promoter methylation with the expression of H19 and IGF-II genes in adrenocortical tumors. , 2002, The Journal of clinical endocrinology and metabolism.

[144]  E. Baudin,et al.  Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. , 2001, Cancer research.

[145]  I. Francis,et al.  Delayed enhanced CT of lipid-poor adrenal adenomas. , 2000, AJR. American journal of roentgenology.

[146]  C. Gicquel,et al.  Fibroblast Growth Factor-2 Inhibits the Maturation of Pro-Insulin-Like Growth Factor-II (Pro-IGF-II) and the Expression of Insulin-Like Growth Factor Binding Protein-2 (IGFBP-2) in the Human Adrenocortical Tumor Cell Line NCI-H295R. , 2000, Endocrinology.

[147]  J. Rastad,et al.  PET imaging of adrenal cortical tumors with the 11beta-hydroxylase tracer 11C-metomidate. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[148]  G. Arnaldi,et al.  A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. , 2000, The Journal of clinical endocrinology and metabolism.

[149]  K. Salmenkivi,et al.  P53 and Ki67 in Adrenocortical Tumors , 2000, Endocrine research.

[150]  E. Speel,et al.  Analysis of genomic alterations in sporadic adrenocortical lesions. Gain of chromosome 17 is an early event in adrenocortical tumorigenesis. , 1999, The American journal of pathology.

[151]  C. Larsson,et al.  Genotyping of adrenocortical tumors: very frequent deletions of the MEN1 locus in 11q13 and of a 1-centimorgan region in 2p16. , 1999, The Journal of clinical endocrinology and metabolism.

[152]  D. Szolar,et al.  Adrenal adenomas and nonadenomas: assessment of washout at delayed contrast-enhanced CT. , 1998, Radiology.

[153]  C. Gicquel,et al.  Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1998 by The Endocrine Society Increased Levels of Insulin-Like Growth Factor II (IGF-II) and IGF-Binding Protein-2 Are Associated with Malignancy in Sporadic Adrenocortical Tum , 2022 .

[154]  L. Quint,et al.  CT time-attenuation washout curves of adrenal adenomas and nonadenomas. , 1998, AJR. American journal of roentgenology.

[155]  C. Larsson,et al.  Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. , 1996, Cancer research.

[156]  G. Chrousos,et al.  p53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. , 1994, The Journal of clinical endocrinology and metabolism.

[157]  P Blondeau,et al.  Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. , 1990, The New England journal of medicine.

[158]  D. Ross,et al.  Incidentally discovered adrenal masses. , 1989, American journal of surgery.

[159]  L. Medeiros,et al.  Pathologic Features of Prognostic Significance in Adrenocortical Carcinoma , 1989, The American journal of surgical pathology.

[160]  W. Sippell,et al.  Evidence of 11 beta‐hydroxylase deficiency in childhood adrenocortical tumors. The plasma corticosterone/11‐deoxycorticosterone ratio as a possible marker for malignancy , 1987, Cancer.

[161]  H. Slooten,et al.  Morphologic characteristics of benign and malignant adrenocortical tumors , 1985, Cancer.

[162]  K Kinoshita,et al.  Measurement of urinary steroid profile in patients with adrenal tumor as a screening method for carcinoma. , 1985, Endocrinologia japonica.

[163]  L. Weiss Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors , 1984, The American journal of surgical pathology.

[164]  D. Page,et al.  Prognostic factors in adrenal cortical tumors. A mathematical analysis of clinical and morphologic data. , 1979, American journal of clinical pathology.

[165]  S. Jolly,et al.  Adrenocortical Carcinoma , 2010, Cancers.

[166]  J. Bertherat,et al.  Identification of a CpG island methylator phenotype in adrenocortical carcinomas. , 2013, The Journal of clinical endocrinology and metabolism.

[167]  M. Esteller,et al.  DNA methylation and cancer. , 2010, Advances in genetics.

[168]  W. Young Clinical practice. The incidentally discovered adrenal mass. , 2007, The New England journal of medicine.

[169]  W. Wadsak,et al.  Positron emission tomography imaging of adrenal masses: (18)F-fluorodeoxyglucose and the 11beta-hydroxylase tracer (11)C-metomidate. , 2004, European journal of nuclear medicine and molecular imaging.

[170]  P. De Giuli,et al.  Immunohistochemical assessment of Ki-67 in the differential diagnosis of adrenocortical tumors. , 2001, Urology.

[171]  E. Małunowicz,et al.  Heterogeneity of urinary steroid profiles in children with adrenocortical tumors. , 1995, Hormone research.